Tolerogenic peptide from dust mite allergen induces immune tolerance in transgenic mice for allergy treatment | Research

The takeaway

A pan-HLA-DR binding peptide (apitope D121B) from dust mite allergen Der p 1 induced immune tolerance against the full allergen in HLA-DR4 transgenic mice, offering a safer peptide immunotherapy approach for allergic rhinitis and asthma.

Tolerance without anaphylaxis risk
Apitope D121B bypasses antigen processing and mast cell activation to induce tolerance against dust mite allergen—safer than traditional immunotherapy

What the researchers found

Pan-DR binding peptide D identified from in silico prediction. Elevated response in 25 HDM-sensitized patients. Minimal epitope D121B: verified as antigen-processing independent (apitope). Induced tolerance against Der p 1 in HLA-DR4 transgenic mice in vivo.

Why it matters

Current allergen immunotherapy carries anaphylaxis risk and requires years of treatment. Tolerogenic peptides could provide safer, more targeted allergy treatment by directly silencing pathogenic T-cells without activating mast cells.

How the study worked

In silico epitope prediction. Synthetic peptide panel (A-E). PBMC screening in 45 participants (25 HDM-sensitized, 10 atopic controls, 10 healthy). Minimal epitope mapping. Apitope validation and tolerance induction in HLA-DR4 transgenic mice.

What this study cannot tell us

Preclinical (transgenic mice). Single HLA-DR allele tested. Translation to human immune diversity needs evaluation. Clinical efficacy in patients not yet demonstrated.

How to read the evidence

Translational study with human PBMC screening and transgenic mouse validation. Good proof of concept.

When this study was published

Published in 2025.

The bigger picture

Peptide immunotherapy represents the future of allergy treatment—precise, safe, and mechanism-based. This study adds another validated apitope to the growing pipeline of tolerogenic peptides for allergic diseases.

Questions still open

Will D121B induce tolerance across multiple HLA-DR types in humans?
How does apitope therapy compare to sublingual immunotherapy?
Could multiple apitopes be combined for comprehensive Der p 1 tolerance?

Common questions

What is peptide immunotherapy for allergies?

Instead of injecting whole allergen extracts (which can cause allergic reactions), peptide immunotherapy uses small, specific pieces of the allergen that teach the immune system tolerance without triggering mast cells. This study identified a specific dust mite peptide (D121B) that does this safely.

Could this replace allergy shots?

Potentially. Current allergy immunotherapy requires years of regular injections with whole allergen and carries anaphylaxis risk. Tolerogenic peptides like D121B could be safer and possibly faster-acting because they directly target the pathogenic T-cells. Clinical trials in humans are needed.

Read the original research

A dominant, pan-DR binding epitope of Der p 1 in house dust mite allergy induces tolerance in HLA-DR4 transgenic mice.

Frontiers in immunology, 16, 1569283

View on PubMed ↗Publisher’s paper ↗

Citation

Streeter, Heather B; Lucas, Lora G; West, Robert M; Krishna, Mamidipudi T; Wraith, David C. (2025). A dominant, pan-DR binding epitope of Der p 1 in house dust mite allergy induces tolerance in HLA-DR4 transgenic mice.. Frontiers in immunology, 16, 1569283. https://doi.org/10.3389/fimmu.2025.1569283